Nitroprusside

Vasodilator — CARDIOVASCULAR SYSTEM

Key facts

Nitroprusside is a drug in the Vasodilator class catalogued in DrugCentral. It was first approved by the FDA in 1974. DrugCentral lists 2 molecular targets, including NPR1 and GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3. Recorded indications include Acute exacerbation of chronic congestive heart failure, Acute heart failure, Controlled Hypotension and Decompensated cardiac failure.

• Drug class: Vasodilator.
• Molecular targets: NPR1 and GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3 (2 listed in DrugCentral).
• Indications: Acute exacerbation of chronic congestive heart failure, Acute heart failure, Controlled Hypotension, Decompensated cardiac failure and Hypertensive disorder and others.
• ATC code: C02DD01 (Nitroferricyanide derivatives).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Acute exacerbation of chronic congestive heart failure
• Acute heart failure
• Controlled Hypotension
• Decompensated cardiac failure
• Hypertensive disorder
• Hypertensive urgency
• Malignant essential hypertension

Contraindications (14)

• Acute cerebrovascular insufficiency
• Acute nephropathy
• Anemia
• Benign intracranial hypertension
• Chronic obstructive lung disease
• Coarctation of aorta
• Cobalamin deficiency
• Disease of liver
• Disorder of brain
• Hyponatremia
• Hypothyroidism
• Hypovolemia
• Leber's optic atrophy
• Tobacco amblyopia

Mechanism & targets

• Established pharmacologic class: Vasodilator

Molecular targets (2)

Target	Gene	Action	Activity
Atrial natriuretic peptide receptor 1	NPR1	unknown	—
Soluble guanylate cyclase	GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3	activator	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-08-25	PMDA	—	MARUISHI PHARMACEUTICAL Co., Ltd
1974-05-10	FDA	—	ROCHE

ATC classification

ATC code	Therapeutic hierarchy
C02DD01	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON › Nitroferricyanide derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Fear	96.4
Toxicity to various agents	96.1
Renal failure	92.2
Renal injury	71.1
Anhedonia	69.9
Unevaluable event	63.5
Hypotension	59.3
Blood cyanide increased	58.2
Multiple organ dysfunction syndrome	51.8
Emotional distress	49.7

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: 73415791

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nitroprusside used for?

DrugCentral lists the following indications for Nitroprusside: Acute exacerbation of chronic congestive heart failure, Acute heart failure, Controlled Hypotension, Decompensated cardiac failure, Hypertensive disorder, Hypertensive urgency and Malignant essential hypertension.

How does Nitroprusside work?

Its molecular targets in DrugCentral include NPR1 and GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3 (activator).

When was Nitroprusside first approved?

Nitroprusside was first approved by the FDA in 1974.

What drug class does Nitroprusside belong to?

Nitroprusside is in the Vasodilator class.

Sources

• DrugCentral drug card 4631 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL136478 — compound record and bioactivity
• PubChem CID 73415791 — chemical identifiers
• DrugBank DB00325 — drug record
• FDA UNII 169D1260KM — substance identity
• DailyMed: FDA labels for Nitroprusside — current prescribing information (label search)
• UniProt P16066 (NPR1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.